Literature DB >> 10729137

Evidence for a bidirectional element located downstream from the herpes simplex virus type 1 latency-associated promoter that increases its activity during latency.

H Berthomme1, J Lokensgard, L Yang, T Margolis, L T Feldman.   

Abstract

Herpes simplex virus type 1 (HSV-1) latent infection in vivo is characterized by the constitutive expression of the latency-associated transcripts (LAT), which originate from the LAT promoter (LAP). In an attempt to determine the functional parts of LAP, we previously demonstrated that viruses harboring a DNA fragment 3' of the LAT promoter itself were able to maintain detectable promoter expression throughout latency whereas viruses not containing this element could not (J. R. Lokensgard, H. Berthomme, and L. T. Feldman, J. Virol. 71:6714-6719, 1997). This element was therefore called a long-term expression element (LTE). To further study the role of the LTE, we constructed plasmids containing a DNA fragment encompassing the LTE inserted into a synthetic intron between the reporter lacZ gene and either the LAT or the HSV-1 thymidine kinase promoter. Transient-expression experiments with both neuronal and nonneuronal cell lines showed that the LTE locus has an enhancer activity that does not activate the cytomegalovirus enhancer but does activate the promoters such as the LAT promoter and the thymidine kinase promoter. The enhancement of these two promoters occurs in both neuronal and nonneuronal cell lines. Recombinant viruses containing enhancer constructs were constructed, and these demonstrated that the enhancer functioned when present in the context of the viral DNA, both for in vitro infections of cells in culture and for in vivo infections of neurons in mouse dorsal root ganglia. In the infections of mouse dorsal root ganglia, there was a very high level of promoter activity in neurons infected with viruses bearing the LAT promoter-enhancer, but this decreased after the first 2 or 3 weeks. By 18 days postinfection, neurons harboring latent virus without the enhancer showed no beta-galactosidase (beta-gal) staining whereas those harboring latent virus containing the enhancer continued to show beta-gal staining for long periods, extending to at least 6 months postinfection, the longest time examined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729137      PMCID: PMC111871          DOI: 10.1128/jvi.74.8.3613-3622.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  The host-cell architectural protein HMG I(Y) modulates binding of herpes simplex virus type 1 ICP4 to its cognate promoter.

Authors:  C A Panagiotidis; S J Silverstein
Journal:  Virology       Date:  1999-03-30       Impact factor: 3.616

2.  Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1.

Authors:  D L Rock; A B Nesburn; H Ghiasi; J Ong; T L Lewis; J R Lokensgard; S L Wechsler
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene "anti-sense" transcript by in situ hybridization.

Authors:  K D Croen; J M Ostrove; L J Dragovic; J E Smialek; S E Straus
Journal:  N Engl J Med       Date:  1987-12-03       Impact factor: 91.245

4.  Detection of herpes simplex virus type 1 transcripts during latent infection in mice.

Authors:  J G Spivack; N W Fraser
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

5.  RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons.

Authors:  J G Stevens; E K Wagner; G B Devi-Rao; M L Cook; L T Feldman
Journal:  Science       Date:  1987-02-27       Impact factor: 47.728

Review 6.  An inquiry into the mechanisms of herpes simplex virus latency.

Authors:  B Roizman; A E Sears
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

7.  Activation of the TFIID-TFIIA complex with HMG-2.

Authors:  B M Shykind; J Kim; P A Sharp
Journal:  Genes Dev       Date:  1995-06-01       Impact factor: 11.361

8.  RNA from an immediate early region of the type 1 herpes simplex virus genome is present in the trigeminal ganglia of latently infected mice.

Authors:  A M Deatly; J G Spivack; E Lavi; N W Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

9.  Effect of the transcription start region of the herpes simplex virus type 1 latency-associated transcript promoter on expression of productively infected neurons in vivo.

Authors:  M J Farrell; T P Margolis; W A Gomes; L T Feldman
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections.

Authors:  X Chen; M C Schmidt; W F Goins; J C Glorioso
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  17 in total

1.  Multiple immediate-early gene-deficient herpes simplex virus vectors allowing efficient gene delivery to neurons in culture and widespread gene delivery to the central nervous system in vivo.

Authors:  C E Lilley; F Groutsi; Z Han; J A Palmer; P N Anderson; D S Latchman; R S Coffin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region.

Authors:  H Berthomme; J Thomas; P Texier; A Epstein; L T Feldman
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  The herpes simplex virus type 1 latency-associated transcript (LAT) enhancer/rcr is hyperacetylated during latency independently of LAT transcription.

Authors:  Nicole J Kubat; Antonio L Amelio; Nicole V Giordani; David C Bloom
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Deacetylation of the herpes simplex virus type 1 latency-associated transcript (LAT) enhancer and a decrease in LAT abundance precede an increase in ICP0 transcriptional permissiveness at early times postexplant.

Authors:  Antonio L Amelio; Nicole V Giordani; Nicole J Kubat; Jerome E O'neil; David C Bloom
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters.

Authors:  Anna R Cliffe; David A Garber; David M Knipe
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

6.  Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity.

Authors:  Yoshitaka Miyagawa; Pietro Marino; Gianluca Verlengia; Hiroaki Uchida; William F Goins; Shinichiro Yokota; David A Geller; Osamu Yoshida; Joseph Mester; Justus B Cohen; Joseph C Glorioso
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

Review 7.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

8.  Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle.

Authors:  Guey-Chuen Perng; Clinton Jones
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-15

9.  Investigation of the mechanism by which herpes simplex virus type 1 LAT sequences modulate preferential establishment of latent infection in mouse trigeminal ganglia.

Authors:  Yumi Imai; Kathleen Apakupakul; Philip R Krause; William P Halford; Todd P Margolis
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5' end of the latency-associated transcript produces a protein in infected rabbits.

Authors:  Guey-Chuen Perng; Barak Maguen; Ling Jin; Kevin R Mott; John Kurylo; Lbachir BenMohamed; Ada Yukht; Nelson Osorio; Anthony B Nesburn; Gail Henderson; Melissa Inman; Clinton Jones; Steven L Wechsler
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.